CL2007003010A1 - Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03). - Google Patents
Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03).Info
- Publication number
- CL2007003010A1 CL2007003010A1 CL2007003010A CL2007003010A CL2007003010A1 CL 2007003010 A1 CL2007003010 A1 CL 2007003010A1 CL 2007003010 A CL2007003010 A CL 2007003010A CL 2007003010 A CL2007003010 A CL 2007003010A CL 2007003010 A1 CL2007003010 A1 CL 2007003010A1
- Authority
- CL
- Chile
- Prior art keywords
- core
- erodible
- coating
- dosage form
- oral dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Virology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Forma de dosificación oral que comprende un núcleo erosionable que comprende una base débil farmacéuticamente activa y un recubrimiento erosionable en torno a dicho núcleo; y procedimiento de preparación (div. Sol. 260-03).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0203298A GB0203298D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
GBGB0203296.9A GB0203296D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
GB0203297A GB0203297D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003010A1 true CL2007003010A1 (es) | 2008-01-25 |
Family
ID=27738830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2007003010A CL2007003010A1 (es) | 2002-02-12 | 2007-10-19 | Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03). |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP1474114B1 (es) |
JP (2) | JP2005526031A (es) |
KR (2) | KR20100086084A (es) |
CN (1) | CN100444833C (es) |
AP (1) | AP1736A (es) |
AR (1) | AR038417A1 (es) |
AT (1) | ATE455540T1 (es) |
AU (1) | AU2003245763B2 (es) |
BR (1) | BRPI0307319B8 (es) |
CA (1) | CA2475544A1 (es) |
CL (1) | CL2007003010A1 (es) |
CO (1) | CO5601025A2 (es) |
CY (1) | CY1109939T1 (es) |
DE (1) | DE60331041D1 (es) |
DK (1) | DK1474114T3 (es) |
EA (1) | EA008286B1 (es) |
EC (1) | ECSP045232A (es) |
ES (1) | ES2336319T3 (es) |
HK (1) | HK1072194A1 (es) |
IL (1) | IL163098A (es) |
IS (1) | IS2747B (es) |
MA (1) | MA27689A1 (es) |
MX (1) | MXPA04007794A (es) |
MY (1) | MY139719A (es) |
NO (1) | NO334453B1 (es) |
NZ (1) | NZ534152A (es) |
OA (1) | OA12770A (es) |
PE (1) | PE20030800A1 (es) |
PL (1) | PL206596B1 (es) |
PT (1) | PT1474114E (es) |
SI (1) | SI1474114T1 (es) |
TW (1) | TWI286079B (es) |
UY (1) | UY27660A1 (es) |
WO (1) | WO2003068195A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0120835D0 (en) | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
AR045330A1 (es) * | 2003-08-07 | 2005-10-26 | Sb Pharmco Inc | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla |
GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
US7879354B2 (en) | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
KR101413613B1 (ko) * | 2006-01-27 | 2014-07-10 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 선택성 세로토닌 5-ht3 차단제와 유기산을 포함하는 약물 전달 시스템 |
RU2428176C2 (ru) * | 2006-01-27 | 2011-09-10 | Юранд, Инк. | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2150830B (en) * | 1983-12-05 | 1987-08-19 | Alza Corp | Drug dispenser |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
EA007610B1 (ru) * | 1998-11-12 | 2006-12-29 | Смитклайн Бичам Плс | Таблетка с энтеропокрытием, обеспечивающая отсроченное высвобождение |
AR023699A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica |
GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
-
2003
- 2003-02-10 MY MYPI20030447A patent/MY139719A/en unknown
- 2003-02-10 PE PE2003000145A patent/PE20030800A1/es active IP Right Grant
- 2003-02-11 UY UY27660A patent/UY27660A1/es not_active IP Right Cessation
- 2003-02-11 TW TW092102772A patent/TWI286079B/zh not_active IP Right Cessation
- 2003-02-11 AR ARP030100422A patent/AR038417A1/es not_active Application Discontinuation
- 2003-02-12 OA OA1200400209A patent/OA12770A/en unknown
- 2003-02-12 PL PL371368A patent/PL206596B1/pl unknown
- 2003-02-12 MX MXPA04007794A patent/MXPA04007794A/es active IP Right Grant
- 2003-02-12 EP EP03739557A patent/EP1474114B1/en not_active Expired - Lifetime
- 2003-02-12 CN CNB038037378A patent/CN100444833C/zh not_active Expired - Lifetime
- 2003-02-12 NZ NZ534152A patent/NZ534152A/en not_active IP Right Cessation
- 2003-02-12 DK DK03739557.1T patent/DK1474114T3/da active
- 2003-02-12 EA EA200401071A patent/EA008286B1/ru not_active IP Right Cessation
- 2003-02-12 CA CA002475544A patent/CA2475544A1/en not_active Abandoned
- 2003-02-12 JP JP2003567378A patent/JP2005526031A/ja not_active Withdrawn
- 2003-02-12 ES ES03739557T patent/ES2336319T3/es not_active Expired - Lifetime
- 2003-02-12 WO PCT/GB2003/000594 patent/WO2003068195A1/en active Application Filing
- 2003-02-12 AT AT03739557T patent/ATE455540T1/de active
- 2003-02-12 AP APAP/P/2004/003087A patent/AP1736A/en active
- 2003-02-12 KR KR1020107015064A patent/KR20100086084A/ko not_active Application Discontinuation
- 2003-02-12 PT PT03739557T patent/PT1474114E/pt unknown
- 2003-02-12 KR KR1020047012361A patent/KR101048925B1/ko active IP Right Grant
- 2003-02-12 AU AU2003245763A patent/AU2003245763B2/en not_active Expired
- 2003-02-12 BR BRPI0307319A patent/BRPI0307319B8/pt not_active IP Right Cessation
- 2003-02-12 SI SI200331764T patent/SI1474114T1/sl unknown
- 2003-02-12 DE DE60331041T patent/DE60331041D1/de not_active Expired - Lifetime
-
2004
- 2004-07-19 IL IL163098A patent/IL163098A/en active IP Right Grant
- 2004-08-05 IS IS7383A patent/IS2747B/is unknown
- 2004-08-09 CO CO04077244A patent/CO5601025A2/es not_active Application Discontinuation
- 2004-08-12 MA MA27822A patent/MA27689A1/fr unknown
- 2004-08-12 EC EC2004005232A patent/ECSP045232A/es unknown
- 2004-08-31 NO NO20043633A patent/NO334453B1/no not_active IP Right Cessation
-
2005
- 2005-04-25 HK HK05103523.5A patent/HK1072194A1/xx not_active IP Right Cessation
-
2007
- 2007-10-19 CL CL2007003010A patent/CL2007003010A1/es unknown
-
2010
- 2010-03-31 CY CY20101100304T patent/CY1109939T1/el unknown
- 2010-04-22 JP JP2010098906A patent/JP5279757B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003010A1 (es) | Forma de dosificacion oral que comprende un nucleo erosionable que contiene un principio activo de caracter basico debil, un recubrimiento erosionable en torno a dicho nucleo con una o mas abertura que atraviesn el recubrimiento y conectan al nucleo con el medio de uso; procedimiento de preparacion; y uso (divisional de 260-03). | |
AR028372A1 (es) | Dispositivos de administracion de drogas de liberacion sostenida, metodos de uso y metodos de fabricacion de los mismos | |
HUP0300472A2 (hu) | Topikális helyi érzéstelenítż alkalmazáshoz való intradermális penetrációs anyagok | |
ATE431738T1 (de) | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist | |
ATE486840T1 (de) | Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür | |
PA8539901A1 (es) | Novedosa sal de succinato de o-desmetil-venlafaxina | |
CY1111825T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη | |
NO20003196L (no) | Umiddelbart opplösende doseringsformulering | |
UY26321A1 (es) | Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes | |
CL2008002407A1 (es) | Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04). | |
IT1302234B1 (it) | Procedimento per la fabbricazione di un dispositivo a semiconduttoreimpiegando una minuta configurazione di resist, e dispositivo a | |
CA2396152A1 (en) | Osmotic device within an osmotic device | |
AR025428A1 (es) | Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asicomo eventualmente otros excipientes | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
CO5190681A1 (es) | Formas de dosificacion farmaceutica para la liberacion controlada que producen al menos un impulso ciclico | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
NO20026037L (no) | Sötvareprodukt som inneholder aktive bestanddeler | |
ID27504A (id) | Formulasi oral baru | |
CL2009001279A1 (es) | Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03). | |
HUP0300722A2 (hu) | Hidrogél segítségével szabályozott gyógyszerforma | |
AR034517A1 (es) | Formulacion farmaceutica | |
ECSP066338A (es) | Nueva composición que comprende rosiglitazona y otro agente antidiabético | |
AR032642A1 (es) | Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral. | |
EE200200653A (et) | alfa-2,4-disulfofenüül-N-tert-butüülnitrooni uuedpreparaadid | |
EA200501565A1 (ru) | Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса |